•The
complement system is a crucial part of innate immune defenses against invading
pathogens
•Inhibiting
activation of C5 has shown great therapeutic benefit in complement-driven
inflammatory diseases, such as atypical haemolytic
uremic syndrome (aHUS)
and paroxysmal nocturnal hemoglobinuria (PNH)
and has potential
in the treatment of various human diseases
•The
novel polypeptide isolated from
Rhipicephalus
pulchellus
tick
saliva is
around 90 residues long, is readily soluble and is chemically and proteolytically
stable
•It
shows a
novel mechanism of C5 inhibition by analysis of the binding interface
